CVKD vs BGMS Comparison

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Bio Green Med Solution Inc is engaged in the supply and trading of protective and fire safety equipment. The company distributes products such as fire extinguishers, foam systems, fire-resistant doors, personal protective equipment, and safety apparel. It also provides fire safety systems, including sprinkler systems, fire alarm systems, valves, and CO2 systems. The company operates across commercial, industrial, healthcare, and residential sectors, with a focus on distribution and compliance with applicable safety standards.